Trial Profile
CLEMENT Capecitabine-radiosensitizing Lutetium-177 octreotate endoradiotherapy management of endocrine neurogenic tumours Response and Toxicity Assessment
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 16 Jul 2019
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Lutetium-(177Lu)-oxodotreotide (Primary) ; Temozolomide (Primary)
- Indications Neuroendocrine tumours
- Focus Therapeutic Use
- Acronyms CLEMENT
- 08 Jun 2016 Status changed from recruiting to completed.
- 28 Jul 2011 New trial record